Works matching AU Bartlett, Nancy L

Results: 108
    1
    2
    3
    4
    5

    Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study.

    Published in:
    Hematological Oncology, 2025, v. 43, n. 3, p. 1, doi. 10.1002/hon.70087
    By:
    • Torka, Pallawi;
    • Grover, Natalie S.;
    • Voorhees, Timothy J.;
    • Karmali, Reem;
    • Annunzio, Kaitlin;
    • Watkins, Marcus P.;
    • Anampa‐Guzmán, Andrea;
    • Reves, Heather;
    • Tavakkoli, Montreh;
    • Christian, Beth;
    • Thomas, Colin;
    • Barta, Stefan K.;
    • Geethakumari, Praveen Ramakrishnan;
    • Bartlett, Nancy L.;
    • Shouse, Geoffrey;
    • Olszewski, Adam J.;
    • Epperla, Narendranath
    Publication type:
    Article
    6
    7
    8

    Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.

    Published in:
    2018
    By:
    • Henderson, Tara O.;
    • Parsons, Susan K.;
    • Wroblewski, Kristen E.;
    • Chen, Lu;
    • Hong, Fangxin;
    • Smith, Sonali M.;
    • McNeer, Jennifer L.;
    • Advani, Ranjana H.;
    • Gascoyne, Randy D.;
    • Constine, Louis S.;
    • Horning, Sandra;
    • Bartlett, Nancy L.;
    • Shah, Bijal;
    • Connors, Joseph M.;
    • Leonard, John I.;
    • Kahl, Brad S.;
    • Kelly, Kara M.;
    • Schwartz, Cindy L.;
    • Li, Hongli;
    • Friedberg, Jonathan W.
    Publication type:
    journal article
    9
    10
    11
    12
    13

    Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma.

    Published in:
    British Journal of Haematology, 2021, v. 194, n. 4, p. 690, doi. 10.1111/bjh.17527
    By:
    • Oluwole, Olalekan O.;
    • Bouabdallah, Krimo;
    • Muñoz, Javier;
    • De Guibert, Sophie;
    • Vose, Julie M.;
    • Bartlett, Nancy L.;
    • Lin, Yi;
    • Deol, Abhinav;
    • McSweeney, Peter A.;
    • Goy, Andre H.;
    • Kersten, Marie José;
    • Jacobson, Caron A.;
    • Farooq, Umar;
    • Minnema, Monique C.;
    • Thieblemont, Catherine;
    • Timmerman, John M.;
    • Stiff, Patrick;
    • Avivi, Irit;
    • Tzachanis, Dimitrios;
    • Kim, Jenny J.
    Publication type:
    Article
    14

    A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.

    Published in:
    Annals of Hematology, 2024, v. 103, n. 1, p. 185, doi. 10.1007/s00277-023-05475-0
    By:
    • Merryman, Reid W.;
    • Redd, Robert A.;
    • Freedman, Arnold S.;
    • Ahn, Inhye E.;
    • Brown, Jennifer R.;
    • Crombie, Jennifer L.;
    • Davids, Matthew S.;
    • Fisher, David C.;
    • Jacobsen, Eric D.;
    • Kim, Austin I.;
    • LaCasce, Ann S.;
    • Ng, Samuel;
    • Odejide, Oreofe O.;
    • Parry, Erin M.;
    • Isufi, Iris;
    • Kline, Justin;
    • Cohen, Jonathon B.;
    • Mehta-Shah, Neha;
    • Bartlett, Nancy L.;
    • Mei, Matthew
    Publication type:
    Article
    15
    16
    17

    Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

    Published in:
    2017
    By:
    • Diefenbach, Catherine S.;
    • Connors, Joseph M.;
    • Friedberg, Jonathan W.;
    • Leonard, John P.;
    • Kahl, Brad S.;
    • Little, Richard F.;
    • Baizer, Lawrence;
    • Evens, Andrew M.;
    • Hoppe, Richard T.;
    • Kelly, Kara M.;
    • Persky, Daniel O.;
    • Younes, Anas;
    • Kostakaglu, Lale;
    • Bartlett, Nancy L.
    Publication type:
    journal article
    18
    19

    Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 7, p. 552, doi. 10.1016/j.clml.2023.04.003
    By:
    • Patel, Dilan A.;
    • Wan, Fei;
    • Trinkaus, Kathryn;
    • Guy, Daniel G.;
    • Edwin, Natasha;
    • Watkins, Marcus;
    • Bartlett, Nancy L.;
    • Cashen, Amanda;
    • Fehniger, Todd A.;
    • Ghobadi, Armin;
    • Shah, Neha-Mehta;
    • Kahl, Brad S.
    Publication type:
    Article
    20

    Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e435, doi. 10.1016/j.clml.2021.12.012
    By:
    • Hamid, Muhammad Saad;
    • Rutherford, Sarah C.;
    • Jang, Hyejeong;
    • Kim, Seongho;
    • Patel, Krish;
    • Bartlett, Nancy L.;
    • Malecek, Mary-Kate;
    • Watkins, Marcus P.;
    • Maddocks, Kami J.;
    • Bond, David A.;
    • Feldman, Tatyana A.;
    • Magarelli, Gabriela;
    • Advani, Ranjana H;
    • Spinner, Michael A;
    • Evens, Andrew M.;
    • Shah, Mansi;
    • Ahmed, Sairah;
    • Stephens, Deborah M.;
    • Allen, Pamela;
    • Tees, Michael T.
    Publication type:
    Article
    21

    Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 5, p. e300, doi. 10.1016/j.clml.2021.10.018
    By:
    • Bennani, N. Nora;
    • Tun, Aung M.;
    • Carson, Kenneth R;
    • Geiger, Jessica L;
    • Maeda, Lauren S;
    • Savage, Kerry J;
    • Rose, Jim;
    • Pinter-Brown, Lauren;
    • Lunning, Matthew A;
    • Abramson, Jeremy S;
    • Bartlett, Nancy L;
    • Vose, Julie M;
    • Evens, Andrew M;
    • Smith, Sonali M;
    • Horwitz, Steven M;
    • Ansell, Stephen M.;
    • Advani, Ranjana H
    Publication type:
    Article
    22

    Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. e250, doi. 10.1016/j.clml.2021.10.004
    By:
    • Bennani, N. Nora;
    • Tun, Aung M.;
    • Carson, Kenneth R.;
    • Geiger, Jessica L.;
    • Maeda, Lauren S.;
    • Savage, Kerry J.;
    • Rose, Jim;
    • Pinter-Brown, Lauren;
    • Lunning, Matthew A.;
    • Abramson, Jeremy S.;
    • Bartlett, Nancy L.;
    • Vose, Julie M.;
    • Evens, Andrew M.;
    • Smith, Sonali M.;
    • Horwitz, Steven M.;
    • Ansell, Stephen M.;
    • Advani, Ranjana H.
    Publication type:
    Article
    23

    TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S411, doi. 10.1016/S2152-2650(21)01925-X
    By:
    • Iyer, Swaminathan;
    • Trümper, Lorenz;
    • O'Connor, Owen A.;
    • Pro, Barbara;
    • Illidge, Tim;
    • Advani, Ranjana;
    • Bartlett, Nancy L.;
    • Christensen, Jacob Haaber;
    • Morschhauser, Franck;
    • Domingo-Domenech, Eva;
    • Rossi, Giuseppe;
    • Won Seog Kim;
    • Feldman, Tatyana;
    • Menne, Tobias;
    • Belada, David;
    • Illès, Árpád;
    • Tobinai, Kensei;
    • Kunihiro Tsukasaki;
    • Su-Peng Yeh;
    • Shustov, Andrei
    Publication type:
    Article
    24

    IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S406, doi. 10.1016/S2152-2650(21)01916-9
    By:
    • Assouline, Sarit;
    • Won Seog Kim;
    • Sehn, Laurie H.;
    • Schuster, Stephen J.;
    • Chan Yoon Cheah;
    • Nastoupil, Loretta J.;
    • Shadman, Mazyar;
    • Sung-Soo Yoon;
    • Matasar, Matthew J.;
    • Diefenbach, Catherine;
    • Gregory, Gareth P.;
    • Bartlett, Nancy L.;
    • Wei, Michael C.;
    • Doral, Michelle Y.;
    • Shen Yin;
    • Negricea, Raluca;
    • Chi-Chung Li;
    • Penuel, Elicia;
    • Huang Huang;
    • Budde, L. Elizabeth
    Publication type:
    Article
    25

    HL-147: Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S371, doi. 10.1016/S2152-2650(21)01849-8
    By:
    • Ramchandren, Radhakrishnan;
    • Dfugosz-Danecka, Monika;
    • Connors, Joseph M.;
    • Radford, John;
    • Illés, Árpád;
    • Picardi, Marco;
    • Lech-Maranda, Ewa;
    • Feldman, Tatyana;
    • Smolewski, Piotr;
    • Savage, Kerry J.;
    • Bartlett, Nancy L.;
    • Walewski, Jan;
    • Zinzani, Pier Luigi;
    • Hutchings, Martin;
    • Munoz, Javier;
    • Won Seog Kim;
    • Advani, Ranjana;
    • Ansell, Stephen M.;
    • Gallamini, Andrea;
    • Alekseev, Sergey
    Publication type:
    Article
    26

    Poster: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S247, doi. 10.1016/S2152-2650(21)01557-3
    By:
    • Iyer, Swaminathan;
    • Trümper, Lorenz;
    • O'Connor, Owen A.;
    • Pro, Barbara;
    • Illidge, Tim;
    • Advani, Ranjana;
    • Bartlett, Nancy L.;
    • Christensen, Jacob Haaber;
    • Morschhauser, Franck;
    • Domingo-Domenech, Eva;
    • Rossi, Giuseppe;
    • Kim, Won Seog;
    • Feldman, Tatyana;
    • Menne, Tobias;
    • Belada, David;
    • Illès, Árpád;
    • Tobinai, Kensei;
    • Tsukasaki, Kunihiro;
    • Yeh, Su-Peng;
    • Shustov, Andrei
    Publication type:
    Article
    27

    Poster: IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S245, doi. 10.1016/S2152-2650(21)01540-8
    By:
    • Assouline, Sarit;
    • Kim, Won Seog;
    • Sehn, Laurie H.;
    • Schuster, Stephen J.;
    • Cheah, Chan Yoon;
    • Nastoupil, Loretta J.;
    • Shadman, Mazyar;
    • Yoon, Sung-Soo;
    • Matasar, Matthew J.;
    • Diefenbach, Catherine;
    • Gregory, Gareth P.;
    • Bartlett, Nancy L.;
    • Wei, Michael C.;
    • Doral, Michelle Y.;
    • Yin, Shen;
    • Negricea, Raluca;
    • Li, Chi-Chung;
    • Penuel, Elicia;
    • Huang, Huang;
    • Budde, L. Elizabeth
    Publication type:
    Article
    28

    Poster: HL-147: Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S236, doi. 10.1016/S2152-2650(21)01485-3
    By:
    • Ramchandren, Radhakrishnan;
    • Długosz-Danecka, Monika;
    • Connors, Joseph M.;
    • Radford, John;
    • Illés, Árpád;
    • Picardi, Marco;
    • Lech-Maranda, Ewa;
    • Feldman, Tatyana;
    • Smolewski, Piotr;
    • Savage, Kerry J.;
    • Bartlett, Nancy L.;
    • Walewski, Jan;
    • Zinzani, Pier Luigi;
    • Hutchings, Martin;
    • Munoz, Javier;
    • Won Seog Kim;
    • Advani, Ranjana;
    • Ansell, Stephen M.;
    • Gallamini, Andrea;
    • Alekseev, Sergey
    Publication type:
    Article
    29

    Oral Abstract: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S203, doi. 10.1016/S2152-2650(21)01276-3
    By:
    • Iyer, Swaminathan;
    • Trümper, Lorenz;
    • O'Connor, Owen A.;
    • Pro, Barbara;
    • Illidge, Tim;
    • Advani, Ranjana;
    • Bartlett, Nancy L.;
    • Christensen, Jacob Haaber;
    • Morschhauser, Franck;
    • Domingo-Domenech, Eva;
    • Rossi, Giuseppe;
    • Won Seog Kim;
    • Feldman, Tatyana;
    • Menne, Tobias;
    • Belada, David;
    • Illès, Árpád;
    • Tobinai, Kensei;
    • Tsukasaki, Kunihiro;
    • Su-Peng Yeh;
    • Shustov, Andrei
    Publication type:
    Article
    30
    31

    Managing Cytokine Release Syndrome and Neurotoxicity with Step-Up Dosing of Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S247, doi. 10.1016/j.clml.2019.07.151
    By:
    • Bartlett, Nancy L.;
    • Sehn, Laurie H.;
    • Assouline, Sarit;
    • Bosch, Francesc;
    • Diefenbach, Catherine M.;
    • Flinn, Ian;
    • Hong, Jung Yong;
    • Kim, Wonseog S.;
    • Matasar, Matthew;
    • Nastoupil, Loretta;
    • Schuster, Stephen J.;
    • Shadman, Mazyar;
    • Yoon, Sung-Soo;
    • Bender, Brendan;
    • Chu, Wayne;
    • Hernandez, Genevive;
    • Kwan, Antonia;
    • McCall, Bruce;
    • Sison, Iris;
    • Wang, Cunlin
    Publication type:
    Article
    32
    33
    34
    35
    36
    37

    Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.

    Published in:
    2001
    By:
    • Bartlett, Nancy L.;
    • Petroni, Gina R.;
    • Parker, Barbara A.;
    • Wagner, Nina D.;
    • Gockerman, Jon P.;
    • Omura, George A.;
    • Canellos, George P.;
    • Cooper, M. Robert;
    • Johnson, Jeffrey L.;
    • Peterson, Bruce A.;
    • Bartlett, N L;
    • Petroni, G R;
    • Parker, B A;
    • Wagner, N D;
    • Gockerman, J P;
    • Omura, G A;
    • Canellos, G P;
    • Robert, M;
    • Johnson, J L;
    • Peterson, B A
    Publication type:
    journal article
    38
    39

    Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.

    Published in:
    Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01448-y
    By:
    • Epperla, Narendranath;
    • Welkie, Rina Li;
    • Torka, Pallawi;
    • Shouse, Geoffrey;
    • Karmali, Reem;
    • Shea, Lauren;
    • Anampa-Guzmán, Andrea;
    • Oh, Timothy S.;
    • Reaves, Heather;
    • Tavakkoli, Montreh;
    • Lindsey, Kathryn;
    • Greenwell, Irl Brian;
    • Hansinger, Emily;
    • Thomas, Colin;
    • Chowdhury, Sayan Mullick;
    • Annunzio, Kaitlin;
    • Christian, Beth;
    • Barta, Stefan K.;
    • Geethakumari, Praveen Ramakrishnan;
    • Bartlett, Nancy L.
    Publication type:
    Article
    40
    41
    42
    43
    44

    Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma.

    Published in:
    Cancers, 2022, v. 14, n. 12, p. 2932, doi. 10.3390/cancers14122932
    By:
    • Jaswal, Shama;
    • Sanders, Vanessa;
    • Pullarkat, Priyanka;
    • Teja, Stephanie;
    • Salter, Amber;
    • Watkins, Marcus P.;
    • Atagu, Norman;
    • Ludwig, Daniel R.;
    • Mhlanga, Joyce;
    • Mellnick, Vincent M.;
    • Peterson, Linda R.;
    • Bartlett, Nancy L.;
    • Kahl, Brad S.;
    • Fehniger, Todd A.;
    • Ghobadi, Armin;
    • Cashen, Amanda F.;
    • Mehta-Shah, Neha;
    • Ippolito, Joseph E.
    Publication type:
    Article
    45

    A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.

    Published in:
    Journal of Hematology & Oncology, 2014, v. 7, n. 1, p. 3, doi. 10.1186/1756-8722-7-44
    By:
    • de Vos, Sven;
    • Forero-Torres, Andres;
    • Ansell, Stephen M.;
    • Kahl, Brad;
    • Cheson, Bruce D.;
    • Bartlett, Nancy L.;
    • Furman, Richard R.;
    • Winter, Jane N.;
    • Kaplan, Henry;
    • Timmerman, John;
    • Whiting, Nancy C.;
    • Drachman, Jonathan G.;
    • Advani, Ranjana
    Publication type:
    Article
    46
    47
    48
    49
    50